Hints and tips:
Related Special Reports
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...AstraZeneca’s chair Michel Demaré told the FT last year that the company was prepared to endure “major criticism” over his pay package in order to keep hold of Soriot....
...another contract manufacturer, said it had received “exploratory inquiries” about “potential supply chain resiliency challenges”, following talks over the Biosecure Act and the acquisition in February of major...
...Eight years after the ill-fated $63bn Monsanto deal, which his predecessor Werner Baumann pushed through despite major shareholder opposition, Anderson is tasked with a near-impossible mission: resurrecting...
...UK ministers are hoping to secure a major new vaccines investment by AstraZeneca with a possible state aid package worth tens of millions of pounds, in a deal that would deliver a big boost to Britain’s...
...The company’s last major acquisition was the $16.6bn takeover of heart device maker Abiomed in November 2022....
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
...But compared with other major investments, scientific breakthroughs come cheap....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
...In a statement on Thursday, the UK-based pharmaceutical company said that it would pay a $3.10-per-share dividend for 2024, 20 cents above the 2023 payout, “underlining the company’s confidence in its performance...
...This could have a major impact in the US, where more than 40 per cent of the population is obese, according to the US Centers for Disease Control and Prevention....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...Witnessing the deaths of these animals puts a major mental strain on scientists as well, he noted....
...WuXi AppTec is a major supplier of essential ingredients to many of the largest global pharmaceutical companies and conducts drug development for them....
...The results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions....
...Ireland has transformed its economy in recent decades, luring investment with low tax rates, a skilled workforce and expertise, as well as EU membership, and life sciences is a major sector....
...An Indian pharmaceutical manufacturer, Intas, is a major supplier of finished dosage methotrexate to the US through its subsidiary Accord Healthcare....
...He is also on the board of US oil major ExxonMobil. Shares in Bayer have fallen 45 cent since Ubben disclosed his stake in January last year, exposing the founder of Inclusive Capital to paper losses....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...The combined group not only controls an estimated 70 per cent of the market for ticketing and live events but it also manages artists and either owns or has exclusive contracts with major concert venues....
International Edition